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Nice guideline on thyroid disease: where
does it take us with liothyronine?
Graham P. Leese
Abstract
The new NICE guidelines on thyroid disease and its management do not recommend the routine use of
liothyronine, but do not completely rule it out either. Guidelines from the British and European Thyroid Associations
are open to a “trial of liothyronine” on an individual basis.
Some patients do not feel well on L-thyroxine despite a serum TSH in the reference range. Key issues to consider in
such patients include establishing whether the patient had established hypothyroidism initially, and whether the L-
thyroxine has been titrated carefully enough, possibly using small increments, to achieve a careful balance between
symptoms and serum TSH concentrations. Patients should also be considered for other causes of the symptoms
which may be wide-ranging.
Meta-analyses of several, but small, randomised control trials show no advantage, or disadvantage of liothyronine
over L-thyroxine. However, detailed sub-analysis identifies some tantalising results eg on preferential weight loss,
patient preference, and possibly genetic markers. Although linked with plausible theoretical explanations, these
results may be over-interpreted. The key questions are whether a short-term trial treatment is worthwhile and safe,
and whether in the future sub-groups of patients can be identified who may benefit from liothyronine. These
questions remain divisive but require additional focussed research.
It could be argued that inflated costs of liothyronine in some countries have either distracted from or helped focus
on the science. Costs need to be addressed. However better biomarkers of tissue level thyroid action, and a better
understanding of the impact of genetic polymorphisms will help to make progress when choosing if there is a
place for liothyronine in the future.
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Background
The debate on whether liothyronine has a role in man-
aging hypothyroidism is akin to entering a cauldron
where there is reasonably clear, but possibly weak, clin-
ical evidence but with intriguing and tantalising ques-
tions in the detail, alongside a strong patient lobby,
Pharmaceutical financial opportunism and Politicians
who are conflicted between a popularist approach and a
need for fiscal responsibility in health-care.
Sorting L-thyroxine prescribing first of all
Titrating the correct dose of L-thyroxine for patients
with primary hypothyroidism is usually straight-forward
but can be challenging in some patients, as around 5–
10% of patients on L-thyroxine have persistent symp-
toms after starting treatment [1, 2]. The goal is to
achieve a balance between symptomatic improvement
and maintaining a serum thyroid-stimulating hormone
(TSH) concentration in the reference range so as to
avoid adverse events [3]. Several patients do seem to
prefer a dose of L-thyroxine that results in a serum TSH
in the lower part of the reference range, and some even
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with a serum TSH below the reference range. The avail-
ability of 12.5 microgram dose strengths of L-thyroxine
makes this titration easier. However, patients are in-
creasingly being started on L-thyroxine at more marginal
baseline serum TSH concentrations [4] often with tran-
sient or marginally abnormal serum TSH where
hypothyroidism is unlikely to be the cause of their symp-
toms. We now realise that the reference range should
probably be expanding, especially in older patients [5].
Some patients do not gain persistent benefit with in-
creasing doses of L-thyroxine despite achieving a low or
even suppressed TSH. Thus careful consideration of
many other potential causes of their symptoms should
be considered, including important conditions such as
hypoadrenalism and anaemia. However, co-prescribed
drugs, sleep apnoea, chronic fatigue, stressful lifestyles
are all more common causes of symptoms that may be
mistaken for non-specific hypothyroid symptoms.
The new National Institute for Clinical Excellence
(NICE) guidelines [6] recommend using L-thyroxine,
with no routine use of liothyronine (section 1.3.4). For
healthy people under the age of 65 a dose of 1.6micro-
gram/kg body weight/day is advised from the start,
whilst those over 65 years or with a history of cardiovas-
cular disease should be started on 25 or 50 microgram
of L-thyroxine. The dose should be adjusted to achieve a
serum TSH within the reference range, acknowledging
that the serum TSH can take some time to change. Most
clinicians will adjust the dose of thyroxine being guided
by both symptom control and serum TSH. This ac-
knowledges that a number of different L-thyroxine doses
may be compatible with a serum TSH in the reference
range.
Main text
Is there a role for Liothyronine?
The NICE guidelines [6] do comment that some patients
who do not feel well on L-thyroxine alone “are some-
times offered liothyronine”. The guideline does not give
a clear recommendation to use Liothyronine but imply
that there may be a role for liothyronine for patients
with adverse symptoms despite seemingly adequate L-
thyroxine replacement, and that more research is
required. The British Thyroid Association [7] and
European Thyroid Association [8] provide clearer guid-
ance. For patients not achieving adequate symptom
control on L-thyroxine where other potential causes of
the symptoms have been excluded, they suggest that
Liothyronine in combination with L-thyroxine may be
considered by a specialist Endocrinologist on a trial basis
whilst maintaining the serum TSH in the reference
range. The trial of liothyronine should be stopped after
3–4 months if there is no patient benefit. However,
across the UK the approach to liothyronine prescribing
has been very variable. In some areas it has proved virtu-
ally impossible to access it, in others there is a fairly re-
stricted approach, whilst in a decreasing number of
areas it has been more freely available.
Is Liothyronine beneficial or harmful compared to L-
thyroxine?
Meta-analyses have compared liothyronine use (alone or
in combination with L-thyroxine) against L-thyroxine
alone, but demonstrated no consistent benefit for
liothyronine use over L-thyroxine alone [6, 9, 10]. Unfor-
tunately, only three of the original studies included more
than 100 patients, and many are under powered. It has
been concluded that liothyronine demonstrates no over-
all benefit and in addition there may be risks. Current
forms of oral liothyronine cause transient non-
physiological elevated serum tri-iodothyronine concen-
trations post-dosing [11], which are not thought to
result in low serum TSH concentrations but may still be
harmful. More flexible dosing regimes of liothyronine
aided by the introduction of 5 microgram tablets, could
make liothyronine dosing easier and potentially safer if
they reduced the risk of raised serum tri-iodothyronine,
although they are unlikely to eliminate this risk. Other
options would include the use of a slow-release prepar-
ation of liothyronine which is being explored.
These same meta-analyses [6, 9, 10] could be inter-
preted that liothyronine is not inferior to L-thyroxine,
and the lack of difference in adverse events [9] as re-
assuring. A 17 year population-based observational fol-
low up study with 400 people on liothyronine also
showed no increase risk of fractures, atrial fibrillation or
cardiovascular disease [12] with patients achieving a
mean serum TSH of 1.1 mU/L during follow up, al-
though there was an increased risk of prescription for
incident psychotropic medication. Intriguingly some
studies showed marginally enhanced weight loss (~ 1.5
kg) on a liothyronine/L-thyroxine combination com-
pared to L-thyroxine alone, whilst patients were
maintaining a serum TSH in the reference range [13,
14]. Also in five cross-over studies more patients pre-
ferred combination therapy rather than L-thyroxine
alone (48% vs 27% - [8]). It is thus possible that there is
a subset of patients who may benefit from liothyronine.
Is there a potential rationale for this or are these find-
ings due to random chance?
L-thyroxine replacement results in higher serum free
thyroxine (T4) concentrations which suppresses deiodi-
nase activity and lowers serum T3 concentrations. Rat
studies required a combination of thyroxine and liothyr-
onine replacement to achieve physiological tissue serum
concentrations [15]. However, similar studies in humans
did not seem to result in improved patient reported out-
comes [8, 16] and in another study serum T4 and serum
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triodothyronine (T3) concentrations were no different
between self-reported “responders” and non-responders”
to liothyronine therapy [17]. This may be because intra-
cellular concentrations of T3 are dependent on a huge
number of factors, including membrane transport pro-
teins, de-iodination, nuclear protein binding e.g. with
retinoid X receptor (RXR) and thyroid hormone recep-
tors, which are all downstream from serum concentra-
tions of thyroid hormones. Hence measuring serum free
thyroxine and liothyronine may not be the way to under-
stand this enigma and we may need novel biomarkers .
Intriguingly other biomarkers have been used in some
studies, and despite similar serum TSH concentrations,
use of liothyronine resulted in lower serum cholesterol,
higher sex hormone binding globulin (SHBG) and in-
creased markers of bone turnover [18–20]. We cannot
however ignore serum TSH, which we do know is a use-
ful marker of long-term patient safety of fractures and
cardiovascular disease [3]. It may be a blunt marker
however with risks increasing significantly only when
the serum TSH was below 0.1 mU/l, despite the lower
limit of the reference range being 0.4 mU/L.
The main enzyme converting T4 to T3 in tissues is
deiodinase 2 (DIO2). Thus the initial studies showing
that a polymorphism on the DIO2 gene was associated
with a better response to liothyronine than the wild type
[2] was intuitive and exciting. However further studies
have not corroborated this finding in follow up [21].
Other polymorphisms on the monocarboxylate trans-
porter 10 (MCT10) thyroid transporter protein, espe-
cially in combination with DIO2 polymorphisms have
also been potentially implicated [22]. Genetic epidemi-
ology is however fraught with false dawns, especially
when studying candidate genes and much larger study
cohorts with replication studies, and GWAS studies are
required in this area before any conclusions can be
drawn.
Costs of Liothyronine
The astronomical increase in costs of liothyronine over
the last 10 years in the UK has resulted in a focus on the
benefits and risks of liothyronine that probably would
otherwise have received less attention given the age of
the drug liothyronine. With the price of liothyronine
20microgram peaking at around £250 per month in the
UK, and following parliamentary activity from the House
of Lords, the number of suppliers has increased from
one to three and the price is starting to fall, currently be-
ing available at £174 per month (at the time of writing).
However this compares with a cost of around £4 ten
years ago, a cost of about £6 per month in Germany and
an equivalent dose cost of around £1 per month for L-
thyroxine. This has also resulted in post-code prescrib-
ing, with patients in the most deprived parts of England
being half as likely to receive a prescription for liothyro-
nine as people in the most affluent areas [23].
Pragmatic approach for now
Thus in summary there is no robust data that liothyro-
nine is of benefit in patients requiring thyroid replace-
ment, which is why guidelines recommend that the vast
majority of patients should be treated with L-thyroxine.
However there are patient reports of benefit and some
intriguing data which may support this. There appears
to be no apparent major risks of using liothyronine as
long as the serum TSH is maintained within the refer-
ence range. Thus careful judicious use of liothyronine
use may be warranted in a few patients who continue to
report adverse symptoms that cannot be attributed to
another cause [7, 8]. Using a combination of L-thyroxine
and liothyronine avoids the need for high doses of
liothyronine, and may thus avoid the concerns of
hyperthyroxinaemia, although it seems this cannot be
eliminated with current formulations [11]. Most studies
use a ratio of 1:5 or 1:4 for Liothyronine to L-thyroxine,
but some have used a 1:3 or a 1:10 ratio. There is no
clear consensus about equivalent doses of L-thyroxine
and Liothyronine but most clinicians reduce the former
by 50microgram and introduce 10–20 microgram of
liothyronine [16]. A long acting preparation of liothyro-
nine is also being explored with the consideration of it
being safer.
What do we need to improve the situation for patients?
Firstly we need to address inappropriate initiation, or
continuation of L-thyroxine. When patients are started
on L-thyroxine inappropriately it is not surprising that
they may not feel better on treatment. There is a great
desire to address a patient’s feelings of lack of well being,
and coupled with the often non-specific symptoms that
can be associated with hypothyroidism and in the
presence of a borderline serum TSH result it is under-
standable to consider treating with L-thyroxine. Thus,
for individuals in such circumstances it may reasonable
to start a “trial” of L-thyroxine for around three months.
Sometimes there can be an immediate benefit but if the
clinical benefit is not maintained then treatment should
not be continued in patients with a baseline borderline
serum TSH, as otherwise it raises unrealistic expecta-
tions about the role of L-thyroxine for them in the long-
term.
Secondly we need better biomarkers to measure the
impact of thyroid replacement therapy. Serum TSH is
probably the best one we have currently, but serum free-
T4 and serum free-T3 concentrations in general do not
reflect the complex intracellular homeostasis of thyroid
physiology.
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Most of the randomised controlled clinical trials of
liothyronine are too small to address some of the clinical
endpoints that are being measured. Some trials may
include patients where the initial diagnosis of
hypothyroidism was questionable but have been estab-
lished on L-thyroxine as explained above. Future trials of
liothyronine should only include patients where the
diagnosis of hypothyroidism is robust, such as having a
TSH of greater than 10 mU/L or a serum free T4 below
the reference range prior to diagnosis. However, the
current trials identify some intriguing results on the use
of liothyronine e.g. weight changes and genetic studies,
which suggest that some subgroups may benefit more
than others, but the trials are too small to draw useful
conclusions. Also it may be best to focus research on pa-
tients who feel unwell on L-thyroxine rather than in-
cluding all patients with hypothyroidism [6]. In addition
as there is a suggestion of variable tissue level effects eg
brain versus liver, further exploration of the differential
impact of liothyronine on symptoms eg brain fog versus
fatigue, may be warranted.
Fourthly, the issue of pricing for liothyronine in the
UK needs to be addressed. Why has the price been
allowed to increase so much in the last 10 years? Why is
the price so much more than other European countries
e.g. more than 30-fold greater? Why has it not decreased
more since the introduction of multiple suppliers and
the breaking of the previous monopoly? There is a need
for procurement teams to negotiate better deals.
Conclusion
There is a sense that the issues surrounding the use of
liothyronine are like a storm in a teacup whipped up by
the winds of pricing. However there are real issues about
benefit and risk which remain scientifically unresolved
unfortunately. A pragmatic approach has been outlined,
but in the future we need to move towards identifying if
there are any subgroups of hypothyroid patients who
may benefit from using liothyronine in addition to L-
thyroxine, probably by identifying novel biomarkers or
genetic polymorphisms.
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